Search Within

Population Sciences Research Program

  1. "Epidemiology and Biostatistics"
  2. "Biostatistics Service"
  3. "Jedd Wolchok"
Formats
  1. Journal Article (57)
  2. Meeting Abstract (38)
  3. Book Section (1)
  4. Research Letter (1)
Groups
  1. Biostatistics Service (97)
  2. Department of Medicine (97)
  3. Epidemiology and Biostatistics (97)
  4. GSK Faculty (97)
  5. Melanoma and Immunotherapeutics Service (97)
  6. Solid Tumor Oncology Division (97)

More Groups

People
  1. Jedd Wolchok (97)
  2. Katherine Panageas (91)
  3. Paul Chapman (57)
  4. Michael Postow (44)
  5. Margaret Callahan (34)
  6. Alexander Shoushtari (27)

More People

Years
  1. 2023 (4)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (8)
  5. 2019 (5)
  6. 2018 (12)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Journal for ImmunoTherapy of Cancer (8)
  3. Clinical Cancer Research (6)
  4. Cancer Research (4)
  5. Melanoma Research (4)
  6. Annals of Surgical Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. American Association for Cancer Research (14)
  3. Biomed Central Ltd (8)
  4. Lippincott Williams & Wilkins (5)
  5. Wiley Blackwell (5)
  6. Nature Publishing Group (4)

More Publishers

Results (97)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
    Meeting Abstract

    Smithy, J. W.; Kalvin, H. L.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy
    Journal Article

    Atkinson, T. M.; Hay, J. L.; Kim, S. Y.; Schofield, E.; Postow, M. A.; Momtaz, P.; Warner, A. B.; Shoushtari, A. N.; Callahan, M. K.; Wolchok, J. D.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma
    Meeting Abstract

    Balachandran, V. P.; Rojas, L. A.; Sethna, Z.; Soares, K.; Derhovanessian, E.; Mueller, F.; Yadav, M.; Basturk, O.; Gonen, M.; Wei, A. C. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
    Journal Article

    Ghosh, A.; Michels, J.; Mezzadra, R.; Venkatesh, D.; Dong, L.; Gomez, R.; Samaan, F.; Ho, Y. J.; Campesato, L. F.; Mangarin, L.; more...
    Journal of Clinical Investigation (2022)

    Fulltext@MSK | Save
  • Adaptive dosing of nivolumab + ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (The ADAPT-IT study)
    Journal Article

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; Smithy, J. W.; Naito, E.; Cugliari, M. K.; Raber, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants
    Meeting Abstract

    Hirschhorn, D.; Budhu, S.; Schröder, D.; Kraehenbuehl, L.; Flammar, A. L.; Chow, A.; Schulze, I.; Schad, S.; Ricca, J.; Gasmi, B.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB)
    Meeting Abstract

    Loo, K.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save